Zydus Lifesciences' North American market sales see strong growth, profit surges unexpectedly
Special Topic: Focus on US Stock Market Q4 2025 Financial Reports
On Monday, Indian pharmaceutical company Zydus Lifesciences Ltd released its financial report, showing that third-quarter profits exceeded market expectations, driven by the launch of new drugs in its largest market, North America.
For the quarter ended December 31, the company reported consolidated profits of 10.42 billion Indian rupees (approximately $115.1 million), up from 10.24 billion Indian rupees in the same period last year.
According to data compiled by London Stock Exchange Group, analysts had previously expected the company’s quarterly profit to decline to 9.32 billion Indian rupees.
The company’s overall revenue increased by 30.3% year-on-year, mainly owing to a 16.4% rise in North American sales and a nearly 13% growth in sales in the domestic Indian market.
Core Background
For most Indian generic drug companies, including Zydus Lifesciences, a majority of their revenue comes from the US market. However, these companies are facing pricing pressures due to intense market competition.
Since early 2025, the launch of new drugs—especially those in Zydus’s specialty drug pipeline—has driven the company’s growth in the US market. During this financial reporting period, the company added four new products to the market.
Meanwhile, Zydus’s peers Cipla and Dr. Reddy’s Laboratories both reported sluggish US sales during the same quarter.
Peer Comparison (Next 12-Month Forecast)
Table
| Zydus Lifesciences Ltd | 14.34 | 7.15 | -10.25 | Hold | 29 | 0.88 | 1.24 |
| Alkem Laboratories Ltd | 12.31 | 10.68 | 22.55 | Buy | 11 | 0.81 | 1.38 |
| Dr. Reddy’s Laboratories Ltd | 13.22 | 3.29 | -10.23 | Hold | 39 | 0.93 | 0.64 |
| Cipla Ltd | 15.09 | 7.85 | 0.62 | Hold | 37 | 0.91 | 0.98 |
* Average Analyst Rating: Standardized average based on the rankings “Strong Buy, Buy, Hold, Sell, Strong Sell”
** Price-to-Target Ratio: The ratio of the latest closing price to the average analyst target price. A value above 1 indicates the current stock price is above the target price.
Stock Performance from October to December
Note: All data comes from London Stock Exchange Group
Exchange rate conversion: 1 USD = 90.5590 Indian rupees
Editor: Guo Mingyu
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
$1,999 Foldable iPhone Is Ready, but Apple (AAPL.US) Faces Over $5.7 Billion Patent Penalty
As Apple intensifies its efforts in foldable displays and AI business, it faces a haptic technology patent compensation ruling exceeding $5.7 billion. On September 25, a federal jury in California found that Apple's Taptic Engine, used in certain iPhone and Apple Watch models, infringed on two patents held by Taction Technology.
Prospects for the opening of the Hormuz Strait are overshadowed, Asian bonds under pressure: 2Y Japanese bond yield approaches 2%, 3Y Korean bond yield rises to highest level since 2022
With high oil prices, short-term bond yields in South Korea and Japan have risen.
5% US Treasury pressure weighs on global assets, while Australian government bonds open up a window for allocation? Fixed income giant Pimco calls the rate hike expectations too aggressive
Pacific Investment Management Company (Pimco) holds a constructive view on Australian bonds, believing that market expectations for rate hikes are too high. Pimco stated that the rate hike cycle in Australia has been "fully priced in," and cracks are beginning to appear in the economy, making Australian bonds look attractive, especially in the 5- to 10-year segment of the yield curve.
Only a few stocks are rising! Goldman Sachs warns: US stock market breadth hits the worst level since the 2000 internet bubble, with rare divergence in bond volatility
Flood, a Goldman Sachs partner, believes that leading AI companies are propping up the market indexes, while median stocks have fallen 16% from their highs. More unusually, Garrett, the head of derivatives trading at Goldman Sachs, warns that the bond volatility MOVE index is at an extremely high percentile, yet the VIX remains subdued. Jonathan Krinsky, a strategist at BTIG, points out that while total hedge fund leverage is rising, net leverage is falling, indicating a contradiction of "increasing exposure without increasing direction," and warns: "Something has to give."
Crypto prices
More
